- December 2016 - GmbH Foundation
- December 2016 - The High-Tech Gründerfonds (HTGF) invests in TolerogenixX GmbH as a seed investor
- April 2017 - TolerogenixX successfully completes Phase I study in live kidney transplantation
- December 2017 - TolerogenixX receives funding (KMU Innovativ) from the Federal Ministry of Economics and Research
1st prize at the Science 4 Life Venture Cup 2015
14. July 2015
Frankfurt am Main (ots) - TolerogenixX from Heidelberg wins with a therapy that significantly improves the quality of life of organ transplanted patients
The founders of Science4Life e. V. the signs point to success:
The patrons, the Hessian Minister of Economic Affairs Tarek Al-Wazir and Prof. Dr. Jochen Maas, Research Director of Sanofi-Aventis Deutschland GmbH, were delighted with the record number of business ideas submitted and praised the ten best founding teams for their innovative ideas and entrepreneurial courage.
At the final award ceremony at the Deutsche Bundesbank's head office, the winning teams received not only plenty of praise but also prize money totalling 56,000 euros. The first prize was awarded to TolerogenixX for the development of a tailored therapy without side effects in transplantation and for patients with autoimmune diseases.
Award for the 1st prize-winners of the Venture Cup 2015
28. July 2015
The science4Life e.V. office is pleased to announce the Tolerogenixx-Team as the winners of the Venture Cup 2015 and to officially hand over the seal of quality to them.